Hormonal
Compounded GLP-1 receptor agonists (semaglutide, tirzepatide) are widely marketed for weight loss in Colorado, but these products lack FDA approval for safety and efficacy, are often mislabeled as 'generic' or 'FDA-approved', and may contain unsafe additives like BPC-157 or unapproved salt forms.
Be aware that compounded GLP-1 drugs sold directly to consumers are not FDA-approved for safety or efficacy. They may contain impurities, incorrect doses, or unsafe additives like BPC-157. Marketing claims of 'FDA approval' or 'generic' status are misleading. Consult a healthcare provider to understand the risks and legal status of these products.
This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products.
Why this rating
Cross-sectional observational study of advertising claims, not a clinical trial of efficacy.
Source
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
Michael J. DiStefano et al. · Journal of Pharmaceutical Policy and Practice · 2024
DOI 10.1080/20523211.2024.2441220
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →